Novachem is the Australian distributor for HepaScore® reagents from Wako Diagnostics. The HepaScore® method, developed in Australia at the University of Western Australia (UWA), has minimal risks associated with patient diagnosis when compared to other fibrosis tests.
HepaScore® method testing is currently being reviewed by MSAC to have Medicare cost codes applied and this will be available to testing facilities in the near future, although the method and reagents are available now under licence.
New treatments for chronic hepatitis virus (HCV) infection (direct acting antiviral (DAA) therapy), were recently listed on the Pharmaceutical Benefits Scheme (PBS). Documentation of the presence or absence of cirrhosis is required for PBS eligibility for DAA therapy. Formal evaluation for cirrhosis with a non-invasive test, such as HepaScore®, is recommended for all individuals.
HepaScore® testing offers substantial cost savings per test compared to invasive testing methods and can be purchased in a range of test kit sizes depending on your requirments.
Novachem also provides a wide range of certified reference materials for clinical and diagnostic laboratories in forensic standards, pharmaceuticals and therapeutic drugs sourced from global leaders in reference standards.
For more information, complete this form and we'll provide more information for you about getting access to this new testing method and reagents.